Boston Partners Dynavax Technologies Corp Transaction History
Boston Partners
- $80.6 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding DVAX
# of Institutions
274Shares Held
130MCall Options Held
451KPut Options Held
203K-
Black Rock Inc. New York, NY21.9MShares$272 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT12.5MShares$156 Million5.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.22MShares$115 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.33MShares$103 Million7.62% of portfolio
-
State Street Corp Boston, MA7.69MShares$95.5 Million0.0% of portfolio
About DYNAVAX TECHNOLOGIES CORP
- Ticker DVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 126,474,000
- Market Cap $1.57B
- Description
- Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...